Prospect Capital Corporation Announces Results of Cash Tender Offer For Any and All of its Outstanding 3.706% Notes due 2026 NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (the “Company”) today announced the results of its previously announced cash tender offer (the “Tender Offer”) to purchase any and all of the outstanding notes listed below. The Tender Offer was made pursuant to an Offer to Purchase dated April 9, 2025 (the “Offer to Purchase”), which set forth the terms and conditions of the Tender Offer, and the accompanying notice of guaranteed delivery (th...
Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: ...
QC Holdings, Inc. to be Acquired by Prospect Capital Corporation NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- A portfolio company of Prospect Capital Corporation (“Prospect”) (NASDAQ: PSEC) and QC Holdings, Inc. (“QC Holdings” or the “Company”) (OTCPK:QCCO) today announced they have entered into a definitive merger agreement pursuant to which, subject to certain conditions and on the terms set forth in the merger agreement, Prospect would acquire QC Holdings in an all-cash transaction, for $2.00 per share, for a total enterprise value of approximately $115 million (the “Merger”). The Mer...
Prospect Capital Corporation Announces Launch of Cash Tender Offer For Any and All of its Outstanding 3.706% Notes due 2026 NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (the “Company”) today announced that it has commenced a cash tender offer (the “Tender Offer”) to purchase any and all of the outstanding notes listed below. The Tender Offer will expire at 5:00 p.m., New York City time, on April 17, 2025, or any other date and time to which the Company extends the Tender Offer (such date and time, as it may or may not be extended, the “Expiration Time”). The T...
Prospect Capital Corporation Hosting Upcoming Webinar: “Medium Term Notes – Senior Position and Attractive Income” NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) is pleased to host an upcoming webinar for financial professionals titled “Medium Term Notes – Senior Position and Attractive Income”. The webinar will provide attendees an overview of senior unsecured bonds, medium term notes, and how a portfolio can benefit from programmatic bonds through attractive contractual cash income streams, optionality across sizes a...
Prospect Capital’s Credit Ratings Reaffirmed Investment Grade by Egan-Jones Ratings Company NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) ("Prospect", “our”, or “we”) today announced that Egan-Jones Ratings Company ("Egan-Jones") has reaffirmed Prospect’s investment grade issuer and institutional notes credit ratings at BBB, and preferred stock credit ratings at BBB-. "We are very pleased that Egan-Jones has reaffirmed our issuer investment grade credit rating as well as investment grade credit ratings for our institutional notes and preferred s...
Prospect Capital’s Credit Ratings Reaffirmed Investment Grade by Morningstar DBRS with Stable Trend NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) ("Prospect", “our”, or “we”) today announced that Morningstar DBRS ("DBRS") has reaffirmed Prospect’s investment grade issuer and long term senior debt credit ratings at BBB(low), and assigned a revised trend of Stable. "We are very pleased that Morningstar DBRS, which has rated Prospect for many years, has reaffirmed our investment grade credit ratings," said Grier Eliasek, President and Chief Opera...
Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, has amended its existing strategic financing agreements by repaying the revenue interest purchase and sale agreement (“RIPSA”) and increasing the debt facility to $450 million on impro...
Prospect Capital Repays March 2025 Bond and Achieves Track Record of $4.7 Billion in Cumulative Principal Bond Repayments During More Than 20 Year History NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced the full and timely repayment of our convertible bond due March 2025, marking another milestone in Prospect’s long-standing track record of responsible and low debt leverage balance sheet management. With this latest repayment, Prospect has now over our more than 20-year history repaid approximately $4.7...
Two Directors at Prospect Capital Corp bought 43,100 shares at between 4.292USD and 4.301USD. The significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.